ablbio_official

ABL Bio is a research-led biotechnology company, a pioneer in bispecific antibodies for immuno-oncology and neurodegenerative diseases.

[ablbio_official @ablbioinc]

ABL Bio has published a new paper :
Preclinical development of ABL206, a novel bispecific antibody-drug conjugate targeting B7-H3 and ROR1
https://t.co/FQ2ecmH8oE
ABL206 is in phase 1 clinical trial (NCT07612176)

[NEOK Bio @NEOKBio]

NEOK Bio’s CEO, Mayank Gandhi, M.D., recently joined @KarenJagoda on the Empowered Patient Podcast to discuss how bispecific #AntibodyDrugConjugates could address some of the most pressing challenges in solid tumors.
Listen here: https://t.co/ZS9u4fwazS
#ADC #MedEd

[ablbio_official @ablbioinc]

Online Now:
Preclinical Study of ABL209
https://t.co/7nwW62tAAy

[ablbio_official @ablbioinc]

ABL Bio developed, and NEOK Bio has initiated U.S. Phase 1 clinical trials for the bispecific ADC candidates ABL206 (NEOK001) and ABL209 (NEOK002), with the first patient dosing now successfully completed.
https://t.co/azUfFtp3If

[ablbio_official @ablbioinc]

https://t.co/PTR9Lb9Kj5
에이비엘, 'B7-H3xROR1' ADC "내성극복..내약성 차별성"

[ablbio_official @ablbioinc]

https://t.co/eGdCTTaZyA
에이비엘 "곧 美1상", 'EGFRxMUC1 ADC' 개발전략은?

[Molecular Cancer Therapeutics @MCT_AACR]

Online now! Simultaneous publication with an #AACR26 poster: #FirstDisclosure of ABL209 (NEOK002), an EGFRxMUC1 bispecific TOP1i ADC with promising anti-tumor activity and enhanced therapeutic window https://t.co/lqrM70OLkH

[ablbio_official @ablbioinc]

The work for ABL209 has just published in @MCT_AACR as well as poster presentation in #AACR26

[Molecular Cancer Therapeutics @MCT_AACR]

Congratulations to Bora Lee & colleagues on their simultaneous publication—ABL209 (NEOK002): Designing an EGFRxMUC1 Bispecific TOP1i ADC with Promising Anti-tumor Activity & Enhanced Therapeutic Window—presented at #AACR26. Read the article: https://t.co/eUuEcJAg50
#OpenAccess

[ablbio_official @ablbioinc]

ABL Bio will present our IGF1R-based BBB shuttle platform as a poster at the Keystone Symposia. See you at the conference.

[ablbio_official @ablbioinc]

The J.P. Morgan Healthcare Conference is fast approaching! We plan to meet with various companies at the event to explore a range of partnership opportunities. See you all at JPM!

[BiotechTV @BiotechTV]

𝐅𝐫𝐨𝐦 𝐒𝐞𝐨𝐮𝐥: @ablbioinc is emerging as a leader in bi-specific antibodies - with programs in CNS, oncology, and a unique approach to making ADCs bi-specific as well.

Full video: https://t.co/j56y7cZxLD

[ablbio_official @ablbioinc]

Happy new year! I hope 2025 will be a year where all your wishes come true.

[ablbio_official @ablbioinc]

ABL Bio will present our BBB shuttle platform 'Grabody-B' as a poster at the CNS Drug Delivery Summit.

[ablbio_official @ablbioinc]

ABL Bio will attend the ‘2024 Pharmaceutical and Bio Industry Innovation Forum’ hosted by the Korea Health Industry Development Institute on November 27th.

[ablbio_official @ablbioinc]

ABL Bio has completed the manufacturing technology transfer for ABL301, a bispecific antibody candidate for the treatment of neurodegenerative diseases including Parkinson’s disease, to Sanofi, and will receive a milestone of $5 million.

[ablbio_official @ablbioinc]

We announces clinical collaboration to evaluate ABL103 in combination with KEYTRUDA® (pembrolizumab) in patients with solid tumors.

The full press release can be found through the link: https://t.co/e4URByAUGi

[ablbio_official @ablbioinc]

ABL Bio was selected as the 'Most Promising Biologics Drug' development company at the Korea Biopharma Excellence Awards 2024 hosted by IMAPAC 😄

[ablbio_official @ablbioinc]

ABL Bio today announced that ABL503 (ragistomig) patent has been issued in Indonesia and China. ABL503 is being jointly developed with ABL’s global partner I-Mab.

[ablbio_official @ablbioinc]

ABL Bio participated in the World ADC Asia 2024 and presented its bispecific ADC development strategy. The title of the presentation is ‘Exploring the Advantages of Using Bispecific ADCs & Their impact on in vitro activities and toxicity’.

[ablbio_official @ablbioinc]

에이비엘바이오가 7월 3일(수) 오전 8시 40분부터 유튜브를 통해 온라인 간담회를 진행합니다. 많은 관심 부탁드립니다.

유튜브 링크: https://t.co/uKdx9RqapH